Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.

Nieuweboer, A J M; Smid, M; de Graan, A-J M; Elbouazzaoui, S; de Bruijn, P; Eskens, F A L M; Hamberg, P; Martens, J W M; Sparreboom, A; de Wit, R; van Schaik, R H N; Mathijssen, R H J

Nieuweboer, A J M; Smid, M; de Graan, A-J M; Elbouazzaoui, S; de Bruijn, P; Eskens, F A L M; Hamberg, P; Martens, J W M; Sparreboom, A; de Wit, R; van Schaik, R H N; Mathijssen, R H J.

Afiliação

Nieuweboer AJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Smid M; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
de Graan AM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Elbouazzaoui S; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Eskens FA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Hamberg P; Department of Internal Medicine, St. Franciscus Gasthuis, Rotterdam, The Netherlands.
Martens JW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
Sparreboom A; Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
van Schaik RH; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
Mathijssen RH; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Pharmacogenomics J ; 16(6): 519-524, 2016 11.

Article em En | MEDLINE | ID: mdl-26345519

Assuntos

Antineoplásicos/efeitos adversos; Antineoplásicos/farmacocinética; Neutropenia/genética; Variantes Farmacogenômicos; Polimorfismo de Nucleotídeo Único; Taxoides/efeitos adversos; Taxoides/farmacocinética; Adolescente; Adulto; Idoso; Idoso de 80 Anos ou mais; Antineoplásicos/administração & dosagem; Bases de Dados Genéticas; Docetaxel; Feminino; Predisposição Genética para Doença; Humanos; Inativação Metabólica/genética; Masculino; Proteínas de Membrana Transportadoras/genética; Proteínas de Membrana Transportadoras/metabolismo; Taxa de Depuração Metabólica/genética; Pessoa de Meia-Idade; Modelos Genéticos; Neutropenia/induzido quimicamente; Farmacogenética; Fenótipo; Fatores de Risco; Índice de Gravidade de Doença; Taxoides/administração & dosagem; Adulto Jovem

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimorfismo de Nucleotídeo Único / Taxoides / Variantes Farmacogenômicos / Neutropenia / Antineoplásicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google